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1.  The unmet need for 
interventions at treatment 
steps 4 and 5 of asthma 
guidelines
Over 300 million people suffer from asthma 
worldwide, and the prevalence of asthma is predicted to increase 
to over 400 million people globally by 2025.[1] In South Africa 
(SA), approximately 8 - 10% of the population is asthmatic, and 
by country SA is ranked fourth highest in terms of asthma mor-
tality.[2] Of some 3 million SA asthma sufferers, approximately 5% 
have confirmed uncontrolled severe asthma despite being adher-
ent to maximal and optimised therapy. Individuals with asthma 
that is difficult to control consume a disproportionate percentage 
(up to 80%) of asthma-specific healthcare expenditure owing to 
the high cost of hospitalisation, physician visits, and increased 
healthcare utilisation.[3] Moreover, there is considerable morbid-
ity, and an economic burden to patients and the state from days 
lost from school or work.
Currently proposed individual therapies at step 5 of the Global 
Initiative for Asthma (GINA) and British Thoracic Society (BTS)/
Scottish Intercollegiate Guidelines Network (SIGN) guidelines 
favour the use of oral corticosteroids (OCSs) and/or omalizumab. 
Maintenance treatment with oral or systemic corticosteroids is 
associated with serious adverse events such as osteoporosis, fractures 
and disability, an increased risk of serious or fatal infections including 
tuberculosis (TB), peptic ulceration, skin thinning, cataracts and 
diabetes, and their use should be avoided wherever possible. In SA, 
where the incidence of TB in many areas is >1 000/100 000 persons 
per year, the risk of TB is a particular concern.[4] Omalizumab is 
an injectable monoclonal anti-IgE antibody recently approved for 
use in SA for patients with severe allergic asthma (confirmed by 
the presence of increased serum total IgE) uncontrolled on step 4 
treatments. In those who respond (40 - 60% in the first few months), 
monthly injections may need to be continued indefinitely. The cost of 
omalizumab in SA is approximately ZAR175 428 per year (calculated 
in April 2015 for a person weighing 60 - 70 kg with an IgE level of 
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questions and controversies.
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500 - 600 IU/L). Effective, affordable, and 
less toxic therapies are therefore urgently 
needed.[5]
2.  Bronchial thermo­
plasty: What is it and 
how does it work?
Bronchial thermoplasty (BT) is a device-
based intervention that delivers thermal 
energy to the airways via a bronchoscopically 
guided catheter, with the goal of reducing 
airway smooth-muscle mass (Fig.  1). BT 
has been shown to increase the level of 
symptom control and improve quality of life 
in adults (>18 years) with severe asthma, with 
reductions in the frequency of exacerbations 
and asthma-related emergency room (ER) 
visits. BT was approved by the US Food and 
Drug Administration in 2010, and is included 
in several asthma treatment guidelines.[6-8] It is 
viewed as complementary therapy rather than 
a replacement for pharmacotherapy, although 
drug replacement is achieved in some cases. 
BT is not curative, but aims to improve the 
quality of life of asthma sufferers and minimise 
the need for systemic corticosteroid therapy. 
It is performed as an outpatient hospital 
procedure over three treatment sessions by 
a trained pulmonologist under conscious 
sedation, after which the patient returns to 
the primary referring physician for long-term 
asthma management. The BT procedure itself 
has been outlined and reviewed in detail 
elsewhere[9-11] and is summarised in Fig. 1.
The mechanism whereby BT achieves 
these clinical results is unclear. It may atten-
uate bronchoconstriction through altering 
the dynamics of airway smooth-muscle-
induced bronchoconstriction. Indeed, air-
way narrowing in asthma in the context of 
smooth-muscle hypertrophy increases the 
airway resistance 20-fold when compared 
with resistance in normal airways.[12] How-
ever, it seems unlikely that attenuation of 
bronchoconstriction alone is responsible for 
improvements, since improved lung function 
is not consistently seen. Animal studies have 
shown that airways treated at 65oC and 75oC, 
but not 55oC, show a reduction in airway 
responsiveness and smooth-muscle mass that 
persists for 3 years,[13] and in human lungs 
this effect is seen as soon as 1 - 3 weeks after 
BT.[14] BT therefore appears to influence lung 
remodelling and to have a disease-modifying 
effect. A recent study in ten patients with 
severe asthma has shown that 3 months after 
BT, a significant reduction in smooth muscle 
was observed not only in all the treated lung 
lobes but even in the untreated right middle 
lobe, which is not normally subjected to 
BT.[15] Regression in smooth-muscle mass 
has therefore been demonstrated in the larger 
airways (>3 mm in diameter)[13] and in the 
segmental and sub-segmental airways.[15] The 
impact of BT on the more distal airways down 
to the level of the respiratory bronchioles, 
which also contain smooth muscle and are 
an important site of airway obstruction in 
asthma, remains unclear.[16,17] The beneficial 
smooth-muscle-related effects may be due 
to several factors, including direct reduction 
in muscle mass, interference with contractile 
function, reduction in the secretion of 
inflammatory mediators from smooth 
muscle, reduction in muscle inflammation, 
a potential neural mechanism, disruption of 
a potential pacemaker effect, and possibly 
an indirect effect mediated by changes in 
the epithelium or other structures. How ever, 
there are hardly any data on the impact of BT 
on the immuno pathology in human airways, 
or on the impact of other potential smooth-
muscle-specific functions including immune 
modulation and angiogenesis. Interestingly, 
airway smooth-muscle regression associated 
with a reduction in exacerbations has also 
recently been demonstrated with the calcium 
channel blocker gallopamil.[18]
BT is currently offered at 448 sites in 32 
countries, and as of March 2015, more than 
4 100 patients have been treated with BT 
(source: Boston Scientific). The use of BT 
for severe persistent asthma has now been 
endorsed by several guidelines, including 
the British Guideline on the Management 
of Asthma[6] (BTS/SIGN), the UK National 
Institute of Clinical Excellence (NICE)[7] and 
GINA[8] guidelines, the European Respiratory 
Society/American Thoracic Society Guide-
lines on the Evaluation and Treatment of 
Severe Asthma,[19] and the American College 
of Chest Physicians guideline.[20]
This article seeks to clarify the recommen-
dations of the South African Thoracic 
Society and its interventional pulmonology 
subgroup on how BT should be offered and 
used in the SA context. It is anticipated that 
this document will evolve and be updated as 
more evidence becomes available.
3.  What do global and 
national guidelines 
say about BT?
Based on the available evidence (out-
lined in sections 5 and 6 below), BT has 
been en dorsed by several international 
guidelines and professional societies. 
In the international 2014 joint European 
Fig. 1. Outline of the equipment, the BT procedure, and effects on airway smooth muscle. A: Alair 
radiofrequency controller; B: Alair BT catheter tip (basket electrode) with the 5 mm spacer markings 
guiding sequential activations; C: Handle grip controlling expansion of the catheter tip; D: Gel-type return 
electrode to complete the circuit; E: Foot pedal triggering delivery of the radiofrequency-mediated thermal 
energy; F: BT procedure performed using a flexible fibreoptic bronchoscope; G: Catheter in the bronchus 
delivering controlled radiofrequency thermal energy; H: Histological sections of dog bronchial wall before 
(top) and 12 weeks after BT (bottom), showing reduction in airway smooth muscle and preserved integrity 
of the epithelium, mucous glands and subepithelial tissue;[13] I: Biopsies before and after BT in the lower 
lobes of two patients, showing reduction in airway smooth-muscle mass (the percentage of airway smooth-
muscle surface area/total biopsy area) is shown numerically in the sub-figure. From www.btforasthma.
com, reproduced with permission.
FORUM
728       September 2015, Vol. 105, No. 9
Respiratory Society/American Thoracic Society (ERS/ATS) guideline 
on the definition, evaluation and treatment of severe asthma, and 
based on evidence that was evaluated to be strong but of low quality, 
the recommendation was for BT be performed in adults with severe 
asthma in the context of an independent institutional review board 
(research ethics committee)-approved systematic registry or clinical 
study.[19] Contextually, this recommendation placed a higher value 
on avoiding adverse events, on increased use of resources and on 
a lack of understanding about which specific patients may benefit, 
and a lower value on improvement in symptoms and quality of 
life. The statement, prepared before the 5-year AIR2 (Asthma 
Intervention Study-2) data became available, reiterated the need for 
better understanding of the phenotypes of patients responding to 
BT and the effect that BT was having in patients with more severe 
obstructive asthma (forced expiratory volume in 1 second (FEV1) 
<60% of predicted), or those in whom systemic maintenance OCSs 
are used.
The 2014 BTS/SIGN asthma guideline (British Guideline on the 
Management of Asthma) recommends that BT be considered for 
the treatment of adult patients who have poorly controlled asthma 
despite optimal therapy (grade A recommendation).[6] It suggests 
that BT should be undertaken only in centres that have expertise 
in the assessment of ‘difficult-to-control’ asthma and in regularly 
performing fibreoptic bronchoscopic procedures, and reiterates the 
need for research that could better identify patients who could benefit 
from BT.
The 2014 UK NICE guideline endorses the use of BT, provided that 
patients understand the limitations in efficacy and longer-term safety 
(beyond 5 years) and the potential for adverse events.[7] It further 
recommends that the details of all patients undergoing BT should 
be submitted to a ‘difficult asthma registry’, and emphasises that BT 
should be carried out by a respiratory team with special expertise in 
managing difficult and severe asthma.
The GINA revised 2014 report states that BT may be considered 
for some adult patients with severe asthma (evidence grade B).[8] 
GINA states that BT is a potential step 5 treatment option in adult 
patients with uncontrolled asthma despite use of recommended 
therapeutic regimens and referral to a specialist asthma centre.
BT is endorsed by the Asthma and Allergy Foundation of America, 
which urges ‘that health plans and insurance carriers fully cover the 
cost of BT for those whose severe asthma is not well managed by less 
invasive therapies, and whose physicians deem it appropriate’. BT has 
also been endorsed by INTERASMA, a global asthma association,[21] 
which suggests that ‘BT should not be considered as experimental but 
... important option for patients ... and should be covered and paid by 
the social security system and/or private insurance to facilitate the 
accessibility for this special group of patients’. BT is now available 
in ~32 countries and is currently being funded or reimbursed by 
the national health system or medical insurance companies in the 
USA, Australia, the UK, Japan, Switzerland and Germany, among 
others. The American College of Chest Physicians has endorsed such 
reimbursement.[20]
4. Recommendations and approach
4.1 Evaluate difficult­to­control asthmatics. Difficult-to-control 
asthmatics should be investigated to confirm the diagnosis of severe 
asthma (as per the ERS/ATS definition).[19] We recommend that a 
high-resolution computed tomography (HRCT) scan of the lungs be 
performed to exclude alternative diagnoses or those precluding BT, 
including significant bronchiectasis, sarcoidosis, chronic obstructive 
pulmonary disease (COPD), endobronchial TB, bronchial stenosis, 
other endobronchial disease, tracheobronchomalacia, etc., which 
may all masquerade as asthma. Other potential diagnoses such as 
vocal cord dysfunction, and comorbid conditions or other modifiable 
contributory or risk factors, such as gastro-oesophageal reflux 
disease, rhinosinusitis or use of concomitant medication or exposures 
that may subvert asthma control, should be considered. Further 
work-up may include other investigations to rule in alternative 
diagnoses or determine the underlying endotype, including total and 
specific IgE levels, exhaled nitric oxide (FeNO), blood and sputum 
eosinophilia, etc. At each visit, the patient’s inhaler technique should 
be carefully checked, adherence to medication confirmed, and 
environmental modification implemented. These approaches cannot 
be overemphasised, as these factors frequently explain poor asthma 
control.
4.2. Optimise treatment. Patients should have a trial of at 
least 3 months’ treatment with optimal and/or maximal doses of 
inhaled corticosteroids (ICSs) (ICS thresholds that define severe 
asthma are outlined in the ERS/ATS severe asthma guidelines[19]), 
long-acting b2-agonists (LABAs) and/or long-acting muscarinic 
antagonists (LAMAs), and possibly other step 4 and 5 treatments 
(leukotriene receptor antagonists, and/or low-dose theophylline, and/
or omalizumab (if appropriate)) in an attempt to optimise asthma 
control.[6,7] In suitable patients with an appropriately raised serum IgE 
level and sensitivity to aeroallergens, a 4-month trial of omalizumab 
is advised.[6,8] Immunosuppressive treatments such as methotrexate, 
cyclosporine, etc. are toxic but are included as treatments for severe 
asthma in some, but not all, guidelines;[6,18] having limited efficacy, 
they are rarely used and should not be considered as routine 
treatment before considering BT. If used, they should be given for 
a minimum 3-month period, and stopped if there is no response to 
treatment.[6]
While it is unnecessary to try all the abovementioned options, 
these steps are intended to ensure that any potential benefit from 
medical therapy is realised before recommending BT.
4.3 Confirm the diagnosis of severe asthma. If the patient 
remains uncontrolled despite appropriate work-up and optimisation 
of treatment as outlined in 4.1 and 4.2 above, a diagnosis of severe 
asthma can be established as per the ERS/ATS guideline,[19] i.e. 
asthma that remains uncontrolled despite use of GINA step 4 or 5 
therapeutic options (high-dose ICSs, LABAs, leukotriene modifiers, 
theophylline, omalizumab and/or OCSs).
4.4 Use of BT. We recommend that BT be considered and offered 
to patients who remain uncontrolled despite optimal therapy that 
includes maximal doses of ICSs and optimised GINA step 4 and 5 
therapy (see 4.2 above).
4.5 Where should the procedure be performed, and by whom? 
BT should be offered to patients at a facility accredited by the 
Assembly on Interventional Pulmonology of the South African 
Thoracic Society and that has experience in dealing with difficult-
to-control or severe asthma. The procedure should be performed by 
a pulmonologist experienced in performing bronchoscopy and BT. 
Patients should ideally form part of a national and/or international 
registry, or prospective study, so that long-term outcomes can be 
monitored and audited, and optimal patient selection is facilitated. 
Such a registry has been started in SA.
4.6 Recommendations for the procedure. Three sessions of BT 
approximately 3 - 4 weeks apart should be offered, preferably using 
local anaesthesia and conscious sedation where appropriate and 
if tolerated. General anaesthesia may be employed in appropriate 
patients. Periprocedural corticosteroids should be adminstered 
for a total of 5 days, beginning 3 days prior to the procedure. 
Prior to the procedure, spirometry should be performed to ensure 
that the post-bronchodilator predicted FEV1 is within 90% of 
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the prior baseline. The procedure is relatively contraindicated in 
the presence of bronchiectasis because of the risk of infection. 
Other contraindications include the presence of an implantable 
pacemaker, defibrillator or other electronic device, sensitivity to 
any of the medications used during bronchoscopy, and any general 
contraindication to bronchoscopy, including those relevant to fitness, 
sedation and anaesthesia.
4.7 Post­procedural aspects. Patients should be closely monitored 
for exacerbations after the procedure, and those with a post-
procedure FEV1 <80% of their pre-procedure baseline should be 
considered and carefully evaluated for possible hospitalisation should 
they continue to deteriorate (defined as persistently reduced lung 
function, suboptimal oxygen saturation, persistent tachycardia, etc.). 
A chest radiograph should be performed after the procedure if 
clinically indicated, e.g. in the case of suspected pneumothorax, 
segmental or lobar collapse, or suspected aspiration. Routine post-
procedure chest radiography is unnecessary. Patients should be 
reassessed 6 - 12 weeks after their last BT procedure and regularly 
thereafter, and medication dosages, particularly of OCSs (if being 
used), should be reduced over time as appropriate, to the lowest dose 
that maintains asthma control. Patients may report an improvement 
in their symptoms as early as immediately after the first procedure. 
Increasing benefit after the second and third procedure is often 
reported.
4.8 Post­procedure follow­up. We suggest that all BT patients 
be enrolled in a national and international registry so that adverse 
events can be reported and audited. In the immediate post-procedure 
period (within 2 weeks), clinicians should be vigilant concerning 
complications such as asthma exacerbation, lung collapse and lung 
abscess. Data on long-term safety are accumulating.
5.  What is the impact of BT on 
patient­related outcomes?
The clinical effectiveness of BT has been confirmed in two 
prospective cohort feasibility studies,[14,22] three randomised 
controlled trials (RCTs),[23-25] one of which was published in the New 
England Journal of Medicine, and three prospective cohort follow-
up studies interrogating long-term outcomes and safety[26-28] (the 
relevant studies are summarised in Table 1). The AIR trial enrolled 
112 patients with moderate to severe asthma (FEV1 60 - 85% of 
predicted).[23] Patients with three or more lower respiratory tract 
infections (LRTIs) requiring antibiotics in the preceding year, or 
those with recent respiratory tract infections (RTIs), were excluded. 
The BT group showed a significant decrease in mild exacerbations 
(the primary outcome), significant improvement in asthma control 
(ACQ), significant improvement in quality of life (asthma quality-
of-life questionnaire; AQLQ), and significantly increased symptom-
free days.[23] There was no impact on airway responsiveness or lung 
function.
The RISA (Research In Severe Asthma) open-label trial enrolled 34 
patients with severe asthma (FEV1 >50% of predicted) and evaluated 
safety as the primary outcome.[24] Patients with post-bronchodilator 
FEV1 <50% of predicted, >3 LRTIs requiring antibiotics prior to BT, 
or a recent LRTI were excluded from this study. The study found 
that BT was well tolerated in severe asthma. The BT group showed 
an increase in pre-bronchodilator FEV1, improved asthma control 
(ACQ) and improved AQLQ scores, and significantly more subjects 
were weaned from OCSs (a 64% reduction in OCS use).[24] The BT 
participants also had significant reduction in rescue medication use 
at 22 weeks.
The AIR2 study, designed specifically to minimise confounding 
and a placebo effect, enrolled 297 patients in a double-blinded sham-
controlled fashion, where all the enrolled patients had a bronchoscopy 
and catheter insertion, but radiofrequency-generated thermal energy 
was not delivered to the airways in the control group (sham).[25] This 
study enrolled patients with severe asthma (FEV1 >60% of predicted 
and using >1 000 µg beclomethasone per day with or without OCSs 
and omalizumab). Patients with ≥3 prior hospitalisations, ≥3 LRTIs 
in the previous year, ≥4 pulses of OCSs in the previous year, previous 
life-threatening asthma, or a need for ≥10 mg of OCSs per day were 
excluded from the study. The primary outcome was the change 
in the AQLQ. The study found significantly greater patient-level 
improvement in AQLQ in the BT group, and secondary outcomes 
(severe exacerbations and ER visits) were significantly reduced in the 
BT group. Pre-bronchodilator FEV1 did not improve significantly, 
however, and rescue medication use did not decrease significantly in 
the BT group. In addition to the reduction in severe exacerbations 
during the 12-month follow-up period, asthma-related days lost from 
work, school or other activities were also significantly reduced in the 
BT group. Notably, there was a strong placebo effect in the sham-
treated subjects.
A Cochrane-based systematic review and meta-analysis incorpor-
ating all three RCTs concluded that BT in patients with moderate to 
severe asthma provided modest clinical benefit, improved quality 
of life, and lowered rates of asthma exacerbation.[29] However, the 
procedure increased the risk of adverse events during treatment but 
had a reasonable safety profile after treatment. The authors rated the 
overall quality of evidence regarding BT as ‘moderate’. They suggested 
that ‘future research would provide better understanding of the 
mechanisms of action of BT, as well as its effect in different asthma 
phenotypes, or in patients with worsening lung function’. There 
are currently no data on the impact of BT on mortality in severe 
asthma, but it is noteworthy that the percentage of the bronchial 
wall occupied by smooth muscle is increased in fatal asthma (12% in 
segmental bronchi v. 5% in normal subjects).[30]
6.  What is the response rate and who 
is most likely to respond?
In the AIR2 study, 78.9% of BT patients recorded at least a 0.5 change 
in AQLQ score, and there was a ~53% reduction in ED visits for 
BT patients, a ~35% reduction in severe exacerbations experi enced, 
and a ~50% reduction in respiratory-related hospitalisations.[27] In 
several respects, the magnitude of changes are not dissimilar to that 
seen with omalizumab (e.g. a ~25% reduction in exacerbations, and 
a 70% reduction in ED visits).[31-33]
6.1 Who is most likely to respond? In a recent study, Sheshardi 
et al.[9] showed that a good response to BT was associated with more 
gas trapping on HRCT, reduction in specific quantities of ICSs or 
OCSs, and an incremental improvement in the AQLQ score of >0.5. 
The pathogenesis of bronchial asthma is complex and is broadly 
characterised by an interrelating combination of smooth-muscle 
dysfunction, airway remodelling, and T-helper (Th)2- and non-
Th2-related inflammation.[34] Several subgroups of bronchial asthma 
have now been described, including those with high symptom 
counts but minimal eosinophilic inflammation, and those that 
are inflammation dominant but have fewer daily symptoms.[35] 
Phenotypes may also be categorised based on biomarker profiles, and 
some biomarkers (e.g. blood eosinophils, serum periostin, IgE levels, 
FeNO, etc.) predict response to therapy with biological agents that 
target specific inflammatory pathways.[34,36-38] It remains unclear what 
clinical phenotype (e.g. obese v. non obese; those with airway hyper-
responsiveness (AHR) v. those without), endotype or molecular 
phenotype (e.g. atopic v. non-atopic or Th2 v. non-Th2), or genotype 
is most likely to respond to BT.[38] The value of specific biomarkers 
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Table 1. Summary of key clinical studies evaluating the safety, efficacy and long­term outcomes of BT
Study details 
Key inclusion 
criteria
Key exclusion 
criteria Efficacy measures Adverse events Comments
Miller et al.,[14] 2005
Number enrolled: 16
Design: Feasibility 
study
Patients with 
suspected or 
proven lung 
cancer scheduled 
for lung resection 
N/A Safety, airway 
smooth-muscle 
mass reduction in 
the resected lung 
segments
No serious adverse 
events
Decrease in airway 
smooth muscle 
documented
Cox et al.,[22] 2006
Number enrolled: 16
Design: Feasibility 
study
Adults with mild 
to moderate 
asthma
Recent RTI, frequent 
use of recue 
medication
Safety, methacholine 
PC20 at 2 years 
post BT 
No serious 
adverse events, no 
hospitalisations
Mean PC20 increased 
post-BT, increase in 
symptom-free days, 
morning and evening 
peak flows remained 
stable
AIR trial[23] (Cox et al.), 
2007
Number enrolled: 112
Design: RCT
Adults ≤65 years 
with moderate 
to severe asthma 
(FEV1 60 - 85% 
predicted)
Recent RTI and ≥3 or 
more LRTIs requiring 
antibiotics in the 
preceding year
Primary: rate 
of mild asthma 
exacerbation
Secondary: ACQ/
AQLQ
Asthma worsening 
post BT requiring 
hospitalisation (7.6% BT 
v. 4.08% control group), 
but rates of adverse 
events between 6 weeks 
and 12 months were 
equal in the two groups
Decrease in mild 
exacerbations, 
improvements in ACQ/
AQLQ scores, and 
increase in symptom-free 
days
RISA trial[24] (Pavord et 
al.), 2007
Number enrolled: 34
Design: RCT
Adults ≤65 
years on high-
dose ICS/LABA 
with AHR and 
uncontrolled 
symptoms 
(FEV1 <50% of 
predicted)
Post-BD FEV1 <50% 
of predicted, >3 
LRTIs requiring 
antibiotics prior to 
BT, and those who 
had a recent LRTI
Primary: safety
Secondary: ACQ/
AQLQ, OCS and 
ICS dose reduction, 
and FEV1
Hospitalisation in 4/17 
patients (23%) in the 
BT group v. none in the 
control group, mostly 
within 3 days of BT 
procedure, but similar 
rates of hospitalisation 
in post-treatment 
phase compared with 
control group
Overall BT well tolerated 
in severe asthma, increase 
in pre-BD FEV1, increase 
in ACQ/AQLQ scores, 
and increased proportion 
of OCS weaning post BT
AIR2 trial[25] (Castro et 
al.), 2008
Number enrolled: 297
Design: RCT – double 
blind sham controlled
Adults ≤65 years 
on high-dose 
ICS/LABAs 
(FEV1 >60% of 
predicted)
Previous life-
threatening asthma, ≥3 
prior hospitalisations 
or LRTIs in the 
previous year, ≥4 or 
more pulses of OCSs 
in the previous year, 
need for ≥10 mg of 
OCSs per day
Primary: change in 
AQLQ
Secondary: severe 
exacerbations, 
healthcare utilisation
Increased rate of 
hospital admissions 
(8.4% in the BT group 
v. 2% in the control 
group) 
Greater increase in AQLQ 
in BT group, decrease in 
severe exacerbation and 
asthma-related ER visits 
in BT group
AIR 5-year follow-up[26] 
(Thompson et al.), 2011
Number enrolled: 45
Design: Prospective 
cohort
As above As above at baseline Adverse events, 
hospitalisation, FEV1 
and FVC 
No long-term adverse 
events 
Absence of reported clinical 
complications, no increase 
in asthma-related healthcare 
utilisation, stable FEV1 and 
FVC over 5 years
RISA 5-year follow-up[27] 
(Pavord et al.), 2013
Number enrolled: 14
Design: Prospective 
cohort
As above As above at baseline Safety, severe 
exacerbations, lung 
function
No long-term adverse 
events
Decrease in asthma-
related ER visits, 
hospitalisations and FEV1 
maintained post BT
AIR2 5-year follow- 
up[28] (Wechsler et al.), 
2013
Number enrolled: 162
Design: Prospective 
cohort
As above As above at baseline Safety, asthma 
control, severe 
exacerbation, 
asthma-related ER 
visits
No long-term adverse 
events
Decrease in severe 
exacerbation, asthma-related 
ER visits and hospitalisations 
post-BT maintained over the 
follow-up period
N/A = not applicable; PC20 = provocative concentration (concentration of methacholine at which the FEV1 falls by ≥20%); FVC = forced vital capacity.
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to predict response to BT therefore requires 
clarification. As already outlined, severe 
asthmatics with previous life-threatening 
asthma, OCS requirements of >10 mg/d and 
>3 - 4 exacerbations or hospitalisations in 
the preceding year were excluded from the 
clinical trials. Such patients are frequently 
seen in severe asthma clinics in day-to-day 
clinical practice, and studies on the effect 
of BT in this specific subgroup of patients 
are urgently required. Prospective studies 
will be required to delineate exactly which 
phenotype of patient is most suitable for and 
responsive to BT.
7.  What adverse events 
are associated with 
BT?
In the AIR study, four of 66 subjects in 
the BT group (6%) were hospitalised (six 
hospitalisations).[23] In the RISA trial, 
four of the 17 BT-treated patients had 
seven hospitalisations, of which two were 
secondary to the development of segmental 
lobar collapse, and one patient required 
bronchoscopic aspiration of mucus.[24] In the 
AIR2 study, in which 850 bronchoscopies 
were performed (558 BT and 292 sham 
procedures), there were no device-related 
deaths or major adverse events such as 
pneumothorax, exacerbations requiring 
mechanical ventilation, airway stenosis or 
focal airway narrowing. However, during 
the within-BT treatment period, hospitali-
sation occurred more frequently in the BT 
group (8.4%) than in the sham broncho-
scopy group (2%).[25] It is clear from these 
studies that BT can be associated with 
complications requiring immediate post-
procedure hospitalisation due to an asthma 
exacerbation. Periprocedural corticosteroids 
(administered 3 days before, on the day, 
and 1 day after) are given to minimise 
this risk. The risk of hospitalisation must 
be balanced against the long-term clinical 
improvements achieved, including reduc-
tions in exacerbations, absenteeism and 
corticosteroid use.
The long-term safety of BT (up to 5 years) 
has been demonstrated in three studies.[26-28] 
There is no consistent evidence that BT is 
causally associated with bronchial stenosis 
or bronchiectasis. In the AIR2 follow-up 
study, only three of 93 patients developed 
new (n=1) or worsening bronchiectasis 
(n=2) as shown on HRCT; it remains 
unclear whether this was a complication of 
asthma or related to BT. Minor bleeding in 
the airways may sometimes be seen during 
the procedure, but haemoptysis is rare 
(one patient in the AIR2 study developed 
major haemoptysis requiring embolisation 
about 1 month after bronchoscopy).[25] A 
recent case report describes a lung abscess 
that occurred during the first week after a 
single BT treatment session,[39] and another 
reports recurrent atelectasis caused by fibrin 
plugs.[40] These published cases indicate the 
need to remain vigilant during the post-
procedure period.
8.  Is the effect of BT 
sustained, and is it 
cost­effective?
Two prospective cohort studies have shown 
that the beneficial effects of BT are sus-
tained.[27,28] A follow-up of the RISA cohort 
demonstrated that the reductions in 
hospitalisations (70% reduction) and ER 
visits (~66% reduction) were sustained for 
5 years.[27] There was no long-term change in 
the predicted FEV1. A follow-up of the AIR2 
cohort showed that the reduction in severe 
exacerbations (38% reduction, i.e. 52% in the 
12 months preceding BT and ~30% for each 
year of the follow-up period) and ER visits 
(88% reduction) post BT were also sustained 
for 5 years.[28] Although no comparison with 
the control groups was made during this 
follow-up study, the results at least confirm 
sustained benefit across several endpoints.[41]
The estimated comparative 2015 cost of 
BT, including bronchoscopy and physician 
visits at the time of writing, was estimated to 
be ~ZAR120 000, being a one-time cost. A 
cost-effectiveness study in the USA showed 
that in poorly controlled severe persistent 
asthma, with a 5-year view in the base-
case scenario, the cost-effectiveness of BT 
was USD5 495 per quality-adjusted life-year, 
which was below the ‘willingness to pay’ 
threshold of USD50  000 in the USA. [42] 
Further cost-effectiveness studies are 
re quired in different contexts.
9.  Unanswered questions 
and controversies
The AIR2 study[41] has been criticised 
for several reasons. Firstly, as already 
mentioned, it excluded patients with more 
severe asthma who would possibly have 
benefited the most from BT; only 3.7% 
of patients undergoing BT in AIR2 were 
on OCSs, a group that may be considered 
to have more severe asthma, although 
otherwise the patients enrolled met the 
minimal criteria for the definition of severe 
asthma.[25] Secondly, although there was 
potentially significant improvement in the 
predetermined AQLQ-specific primary 
outcome (mean difference of 0.19 between 
the groups), this fell below the threshold for 
a clinically meaningful difference (change 
in AQLQ score >0.5); however, when 
analysed differently, i.e. at an individual 
level (percentage of subjects with an AQLQ 
Table 2. Unanswered questions and outstanding controversies regarding BT
1 What is the mechanism whereby BT reduces smooth-muscle mass in humans and animals, 
and what is its effect on different cellular and structural components of the human airway?
2 What specific phenotypes of severe asthma that remain symptomatic despite optimal 
treatment will best respond to BT? 
3 Do patients with more severe persistent asthma, who were excluded from the clinical 
trials, benefit to the same extent, or more, from BT?
4 Does BT have increasing benefit in those who have partially responded or in whom the 
benefit later lapses?
5 How far beyond 5 years does the BT effect last?
6 Can the same effect be obtained in fewer BT sessions?
7 Is there any incremental benefit from more than three BT sessions, and what parameters 
portend room for further response?
8 In patients with atopic severe persistent asthma and who are suitable for omalizumab (or 
in future other biologicals), should BT be offered in the first instance taking into account 
their comparative efficacy, safety and cost?
9 Are there longer-term (beyond 5 years) safety issues in patients who undergo BT?
10 Should BT should be recommended in an earlier treatment step to attempt to reduce 
costs of multiple drug treatments and the potential morbidity of prolonged uncontrolled 
asthma, or must it be undertaken as a last resort at step 5 when all else has failed?
11 What is the relationship between asthma severity, and other biological factors, and the 
probability of post-procedure complications?
12 Will patients with emphysema or the asthma-COPD overlap syndrome benefit from BT, 
and what parameters should be used to guide the decision to employ it?
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change of >0.5), AQLQ was statistically significantly better in the 
BT-treated than in the sham bronchoscopy group (78.9% v. 64.3%). 
The latter approach is justified when interpreting AQLQ scores, 
which reflect within-group differences better than between-group 
differences.[11] Thirdly, the placebo effect is well recognised in 
asthma trials, and the AQLQ improvement in the sham group 
was probably due to more meticulous and protocol-driven asthma 
care during the trial, as well as standardisation of care before 
recruitment. Given this consideration, the AIR2 study should 
ideally have incorporated a longer run-in period, and in retrospect, 
chosen asthma exacerbation or ER visits as an a priori primary 
outcome. Indeed, there was a significant reduction in exacerbations 
and ER visits, but this was a secondary outcome rather than a 
prespecified primary outcome.[25] Nevertheless, the reduction in 
severe exacerbations was significant, and this is an important 
determinant of patient-related quality of life and utilisation of 
healthcare costs. Fourthly, it has been suggested that there were 
outliers in the control group that could have driven a meaningful 
part of the statistical difference between the groups. However, it 
was clarified that removal of the outlier would still substantially 
reduce ER visits from 84% to 70%. These points have been openly 
debated and are outlined in detail in several editorials and letters to 
the editor.[41,43] Other unanswered questions are outlined in Table 2. 
These include questions related to the mechanism of action of BT 
and the identification of patients most likely to benefit from it.
Conclusions
BT is indicated as a treatment for severe asthma that remains 
uncontrolled despite an optimal trial of step 4 and 5 GINA therapeutic 
options.[8] BT has been shown to significantly lower the rates of 
asthma exacerbation and ER visits, and has shown modest benefits 
in improvement of quality of life scores. The procedure has been 
confirmed to be safe with no significant long-term adverse effects up 
to 5 years after the initial intervention. Complications of BT include 
exacerbations and hospitalisation due to transient worsening of 
asthma symptoms in a small proportion of patients. As this treatment 
is directed towards treating severe asthma, further studies are needed 
to establish both its short-term and longer-term safety (beyond 5 
years) in patients with more severe disease, and those features that 
identify patients most likely to benefit from BT.
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